DynaGen Inc. announced Monday that it has completed aninitial Phase III clinical trial of NicErase-IA and has expandedits development program for the product as a therapy toreduce nicotine withdrawal symptoms, particularly inhospitalized patients who are restricted from smoking.
According to DynaGen (NASDAQ:DYGN) of Cambridge, Mass., theresults of the placebo controlled, double-blind trial suggestedthat the drug was able to prevent the withdrawal symptomsthat commonly occur when cigarette smokers abruptly stopsmoking. The trial also showed that lobeline, the activeingredient, did not exhibit any potential for addition.
Dynagen said it expects to begin its next Phase III study withinthe next two months.
(c) 1997 American Health Consultants. All rights reserved.